Display options
Cite
Zhang L, Cheng Y, Du X, et al. Swertianlarin, an Herbal Agent Derived from Swertia mussotii Franch, Attenuates Liver Injury, Inflammation, and Cholestasis in Common Bile Duct-Ligated Rats. Evid Based Complement Alternat Med. 2015;2015:948376doi: 10.1155/2015/948376.
Zhang, L., Cheng, Y., Du, X., Chen, S., Feng, X., Gao, Y., Li, S., Liu, L., Yang, M., Chen, L., Peng, Z., Yang, Y., Luo, W., Wang, R., Chen, W., & Chai, J. (2015). Swertianlarin, an Herbal Agent Derived from Swertia mussotii Franch, Attenuates Liver Injury, Inflammation, and Cholestasis in Common Bile Duct-Ligated Rats. Evidence-based complementary and alternative medicine : eCAM, 2015948376. https://doi.org/10.1155/2015/948376
Zhang, Liangjun, et al. "Swertianlarin, an Herbal Agent Derived from Swertia mussotii Franch, Attenuates Liver Injury, Inflammation, and Cholestasis in Common Bile Duct-Ligated Rats." Evidence-based complementary and alternative medicine : eCAM vol. 2015 (2015): 948376. doi: https://doi.org/10.1155/2015/948376
Zhang L, Cheng Y, Du X, Chen S, Feng X, Gao Y, Li S, Liu L, Yang M, Chen L, Peng Z, Yang Y, Luo W, Wang R, Chen W, Chai J. Swertianlarin, an Herbal Agent Derived from Swertia mussotii Franch, Attenuates Liver Injury, Inflammation, and Cholestasis in Common Bile Duct-Ligated Rats. Evid Based Complement Alternat Med. 2015;2015:948376. doi: 10.1155/2015/948376. Epub 2015 Jul 27. PMID: 26273316; PMCID: PMC4530240.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2015;2015:948376. doi: 10.1155/2015/948376. Epub 2015 Jul 27.

Swertianlarin, an Herbal Agent Derived from Swertia mussotii Franch, Attenuates Liver Injury, Inflammation, and Cholestasis in Common Bile Duct-Ligated Rats.

Evidence-based complementary and alternative medicine : eCAM

Liangjun Zhang, Ying Cheng, Xiaohuang Du, Sheng Chen, Xinchan Feng, Yu Gao, Shaoxue Li, Li Liu, Mei Yang, Lei Chen, Zhihong Peng, Yong Yang, Weizao Luo, Rongquan Wang, Wensheng Chen, Jin Chai

Affiliations

  1. Department of Gastroenterology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
  2. Department of Traditional Chinese Medicine, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
  3. Department of Pediatrics, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
  4. Chongqing Academy of Chinese Material Medicine, Chongqing 400065, China.

PMID: 26273316 PMCID: PMC4530240 DOI: 10.1155/2015/948376

Abstract

Swertianlarin is an herbal agent abundantly distributed in Swertia mussotii Franch, a Chinese traditional herb used for treatment of jaundice. To study the therapeutic effect of swertianlarin on cholestasis, liver injury, serum proinflammatory cytokines, and bile salt concentrations were measured by comparing rats treated with swertianlarin 100 mg/kg/d or saline for 3, 7, or 14 days after bile duct ligation (BDL). Serum alanine aminotransferase (ATL) and aspartate aminotransferase (AST) levels were significantly decreased in BDL rats treated with swertianlarin for 14 days (P < 0.05). The reduced liver injury in BDL rats by swertianlarin treatment for 14 days was further confirmed by liver histopathology. Levels of serum tumor necrosis factor alpha (TNFα) were decreased by swertianlarin in BDL rats for 3 and 7 days (P < 0.05). Moreover, reductions in serum interleukins IL-1β and IL-6 levels were also observed in BDL rats treated with swertianlarin (P < 0.05). In addition, most of serum toxic bile salt concentrations (e.g., chenodeoxycholic acid (CDCA) and deoxycholic acid (DCA)) in cholestatic rats were decreased by swertianlarin (P < 0.05). In conclusion, the data suggest that swertianlarin derived from Swertia mussotii Franch attenuates liver injury, inflammation, and cholestasis in bile duct-ligated rats.

References

  1. J Ethnopharmacol. 2005 Apr 8;98(1-2):31-5 - PubMed
  2. Biomed Chromatogr. 2015 Mar;29(3):402-9 - PubMed
  3. Eur J Pharm Sci. 2014 Jun 2;56:70-86 - PubMed
  4. Toxicol Sci. 2009 Apr;108(2):247-57 - PubMed
  5. Gastroenterology. 2006 Feb;130(2):465-81 - PubMed
  6. Clin Liver Dis. 2008 Feb;12(1):53-80, viii - PubMed
  7. Hepatology. 2008 Sep;48(3):871-7 - PubMed
  8. J Ethnopharmacol. 2014 May 28;154(1):259-66 - PubMed
  9. Nat Med. 2004 Dec;10(12):1352-8 - PubMed
  10. J Clin Invest. 2003 Dec;112(11):1678-87 - PubMed
  11. J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S111-24 - PubMed
  12. J Ethnopharmacol. 2010 Jul 6;130(1):103-6 - PubMed
  13. Am J Gastroenterol. 2000 May;95(5):1130-8 - PubMed
  14. N Engl J Med. 1998 Oct 22;339(17):1217-27 - PubMed
  15. Exp Clin Cardiol. 2012 Spring;17(1):12-6 - PubMed
  16. J Hepatol. 2009 Sep;51(3):565-80 - PubMed
  17. J Pharm Biomed Anal. 2014 Sep;98:364-70 - PubMed
  18. Inflamm Res. 2014 Jun;63(6):451-62 - PubMed
  19. J Biol Chem. 2003 Dec 19;278(51):51085-90 - PubMed
  20. Liver Int. 2007 Oct;27(8):1056-65 - PubMed
  21. Planta Med. 2009 Jan;75(1):12-7 - PubMed
  22. Gastroenterology. 2006 Mar;130(3):715-20 - PubMed
  23. Hepatology. 2011 Feb;53(2):548-57 - PubMed
  24. Toxicol Appl Pharmacol. 2013 Dec 15;273(3):524-31 - PubMed
  25. Respir Res. 2011 Mar 04;12:26 - PubMed
  26. Semin Liver Dis. 2010 May;30(2):195-204 - PubMed
  27. Evid Based Complement Alternat Med. 2010 Mar;7(1):41-5 - PubMed
  28. Hepatology. 2012 May;55(5):1485-94 - PubMed
  29. J Leukoc Biol. 2013 Jun;93(6):865-73 - PubMed
  30. J Hepatol. 2000;32(1 Suppl):129-40 - PubMed

Publication Types